Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence—a systematic review and meta-analysis

Yikuan Chen1,² · Shaobo Mo1,2 · Mengdi Wu3 · Yaqi Li1,2 · Xi Chen3 · Junjie Peng1,2

Accepted: 29 March 2022 / Published online: 6 April 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract
Purpose Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. After resection, patients need extensive follow-up to detect asymptomatic recurrences as early as possible to obtain optimal treatment. This study evaluated the prognostic value of circulating tumor DNA (ctDNA) for CRC recurrence.
Methods Two investigators independently conducted a systematic literature search of peer-reviewed studies that investigated the prognostic value of ctDNA in CRC. Fixed effects or random effects models were applied for all analyses based on the assessment of heterogeneity.
Results A total of 189 studies were initially retrieved from all databases; ultimately, eight studies with 879 CRC patients were included in this analysis. The pooled median recurrence-free survival was 11.36 months for ctDNA-positive patients. Meta-analysis of hazard ratio (HR) suggested that postoperative ctDNA-positive patients were more likely to experience cancer recurrence than ctDNA-negative patients (pooled HR: 5.41; 95% confidence interval (CI): 2.37–8.45).
Conclusions Successive monitoring of ctDNA status and follow-up with postoperative computed tomography (CT)/magnetic resonance imaging (MRI) are useful tools to detect early recurrence in postoperative ctDNA-positive patients.

Keywords Colorectal cancer · ctDNA · Prognostic indicator · Recurrence · Meta-analysis

Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide, with approximately 1.3 million cases diagnosed annually [1, 2]. The recurrence rate of patients with no detectable tumor cells after first-line treatment is still up to 35% [3, 4]. Since most of these recurrences occur within 2 years, it is suggested that undetected residual disease or micro-metastases may occur [4]. The 5-year survival rate for patients with stage I CRC is 93%, while the 5-year survival rate for patients with stage IV CRC is only 14% [3]. Although the standard tumor staging method based on the depth of tumor invasion, lymph node involvement, and lesion metastasis is more effective for the diagnosis of stage I and IV CRC, it lacks predictive ability for stage II and III patients. Therefore, after radical resection, patients need extensive follow-up to detect asymptomatic recurrences as early as possible to obtain optimal treatment. There are known clinical pathological factors related to the poor prognosis of tumors, such as tumor stage, lymph node involvement, and depth of lesion infiltration, which can help guide adjuvant treatment and postoperative monitoring strategies. However, even in patients without high-risk factors, disease recurrence is common [1, 3, 5].

Carcinoembryonic antigen (CEA) is currently the only biomarker that is included in monitoring guidelines; however, its sensitivity to CRC recurrence is shown to be very low [5–9]. Therefore, it is crucial to find a novel biomarker that can not only assist in screening patients who will benefit from treatment but also be used as a means to detect disease recurrence early during the monitoring period so that patients can be treated in a timely and radical manner.
Studies have shown that circulating tumor DNA (ctDNA) detection, which occurs by genotyping the tumor itself and targeting mutations in ctDNA markers, can alert patients at risk of recurrence [12–23]. However, these somatic mutations associated with CRC progression lack commonality and have a low incidence [24, 25]. Additionally, as cancer cells progress, their heterogeneity becomes stronger, and the reliability of this detection method will be further reduced [26–28].

In recent years, an increasing number of studies have focused on the exploration of ctDNA for the prognosis of CRC, especially the prediction of recurrence after treatment. Our study aims to summarize the results of all relevant studies and use evidence-based medicine to determine the predictive value of ctDNA for CRC recurrence.

Methods

Data sources and searches

The PubMed, Embase, and Cochrane Central Register of Controlled Trials databases were systematically searched by two investigators (Y.C. and M.W.) to identify published or unpublished studies. Additionally, the reference lists of the included studies, recent reviews, editorials, and meta-analyses were manually searched. Peer-reviewed studies that investigated the prognostic value of ctDNA in CRC were selected. All studies were published in English. Studies with no extractable data were excluded from the analysis.

Data extraction and quality assessment

A data extraction form was developed to collect data from each of the included studies. Two investigators independently extracted the following characteristics: study design, cancer type and stage, sample size, ctDNA positivity rate, and duration of follow-up. Extracted data were then compared, and disagreements were resolved by consulting a third person (X.C.).

Data synthesis and analysis

Fixed effects or random effects models were applied for all analyses based on the assessment of heterogeneity, and pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to represent data. We quantified the statistical heterogeneity using I² statistics. Publication bias was assessed through funnel plot asymmetry using Egger’s and Begg’s tests.

The median recurrence-free survival (RFS) time for those with positive postoperative ctDNA results was obtained from KM-Plot using DigitizeIT (www.digitizeit.com) if it was available in full text, and it was pooled using method by McGrath et al. [29].

Subgroup analyses were performed as follows to explore the potential sources of heterogeneity: (1) whether stage IV patients were included in the study; (2) the study setting; (3) the year publication. Two-sided p values <0.05 were considered to be statistically significant. Statistical computations used the standard software STATA/SE v12.0 (StataCorp LP, College Station, TX, USA) and R software version 3.6.2 (R Foundation for Statistical Computing).

Results

Characteristics of the studies

In total, 189 citations were retrieved from all databases. After removing duplicates, 124 citations remained. After reading the abstracts, 26 studies were found to be relevant. Full studies were retrieved and examined. Subsequently, 8 of these met the inclusion criteria (Fig. 1).

The characteristics of the 8 included studies are summarized in Table 1. A total of 879 CRC patients were included in the 8 studies. Three studies included 16 stage IV patients. The funnel plot suggested that there was no evidence of heterogeneity across studies (Fig. 2).

Impact of ctDNA detection on the prognosis of CRC

The pooled median RFS was 11.36 months for ctDNA-positive patients. We could not pool the median RFS for ctDNA-negative patients, as the event did not occur by the time of reporting. Considering that the pooled medium follow-up time of the included studies was 24 months, the pooled RFS for ctDNA-negative patients was no less than 24 months, which was already double that of ctDNA-positive patients (Table 1).

Seven of the 8 included studies reported HR. Meta-analysis of HR suggested that postoperative ctDNA-positive patients were more likely to experience cancer recurrence than ctDNA-negative patients (pooled HR: 5.41; 95% CI: 2.37–8.45) (Fig. 3).

Subgroup analysis and meta-regression analysis

Subgroup analysis showed that studies were published in the past 5 years. The prognostic value of ctDNA was recognized in all studies. Studies in different geographic locations (Europe and Australia) were consistent in the results. The inclusion of stage IV patients did not change the overall conclusion (Table 2). However, studies with stage IV CRC patients had a lower HR (3.96, compared to studies without stage IV patients, HR 8.25), which may indicate that ctDNA might be more reliable as a prognostic indicator for stage I–III patients.
Discussion

Serial radiological examination is the most widely used CRC surveillance method, which subjects patients to significant cumulative radiation doses and has a significant false-positive rate [30]. However, the criterion for radiological assessment is often unclear and questioned [31]. The measurement of blood CEA levels is currently the only guideline recommended blood biomarker for postsurgical monitoring of CRC. A new monitoring method is needed to improve patient survival. Our study is the first systematic review that used meta-analysis to synthesize available data to evaluate the prognostic value of ctDNA in CRC patients after surgery. The main findings can be summarized as follows: (1) detectable ctDNA is a very meaningful indicator of CRC recurrence; (2) this finding was consistently observed in all studies; (3) the results did not
change with study time or location; and (4) ctDNA might be more reliable for predicting the prognosis of stage I–III CRC.

Approximately 2/3 of CRC patients were diagnosed at stage I–III, with localized and potentially curable disease. However, a large portion of patients still experience recurrence after curative surgery [32–34]. Therefore, it is crucial to identify patients at high risk of recurrence so that adjuvant therapy can be offered [35, 36]. Currently, TNM staging is the most widely used approach for estimating the risk of CRC recurrence. However, it has its limitations. ctDNA detection has become a mature technology in many clinical centers around the world. However, due to its higher testing costs and longer testing time, its clinical applications have been largely limited. The number of included studies and samples were relatively small and dispersed for the same reason. Our systematic review synthesized available data from different clinical centers and confirmed the prognostic value of ctDNA as a recurrence indicator of CRC to provide a theoretical basis for future prospective research. Our results support the clinical usage of ctDNA for CRC patients, especially those with stage I–III disease, after curative surgeries in the guidance of adjuvant therapies.

The pooled median RFS was 11.36 months for ctDNA-positive CRC. ctDNA-positive status was associated with shorter survival and disease recurrence in all 3 stages of CRC. As observed by Lecomte et al. [37], the survival time for CRC patients with cfDNA was 2 years shorter than that for those without cfDNA. Their study suggested that ctDNA analysis could distinguish CRC patients with a high risk of recurrence [37]. A significant correlation between ctDNA status and postoperative recurrence was also found by Wang et al. [38]. Tsikitis et al. [39] examined the postoperative recurrence rate by CRC stage and found that the estimated RFS rates at 5 years following surgery were 90% for stage II
patients and 70% for stage III patients. For stage IV patients, the outcome is often poorer, as the 5-year survival rate is less than 10% [40], with a median survival time of approximately 6–12 months.

Curative-intent surgery has become amenable to more CRC patients due to advances in surgical, radiological, and therapeutic options over the past decade. How to monitor patient prognosis after surgery is being widely investigated. Our meta-analysis of HR suggested that postoperative ctDNA-positive patients were more likely to experience cancer recurrence than ctDNA-negative patients (pooled HR: 5.41; 95% CI: 2.37–8.45). Therefore, for postoperative ctDNA-positive patients, successive monitoring of ctDNA status and follow-up with more frequent postoperative computed tomography (CT)/magnetic resonance imaging (MRI) are necessary for early detection of CRC recurrence. Clinical application of ctDNA can be an excellent supplement to the current disease monitoring methods. Personalized assays can be created based on gene mutations that are detected within a tumor biopsy or panel of ctDNA genes to facilitate ongoing ctDNA measurement. Positive or negative ctDNA status can be identified by the presence of a particular gene alteration. Thus, ctDNA measurement can be used as an noninvasive method of tumor monitoring and assessment of therapy response.

Levels of ctDNA dropped following surgery, suggesting preoperative ctDNA correlates with macroscopic tumor burden [41]. Patients with residual disease were significantly more likely to have a positive postoperative ctDNA status. One study that was included in this systematic review specifically focused on the postchemotherapy ctDNA level and risk of disease recurrence and found that assessment of ctDNA at the end of adjuvant therapy showed that a positive result was predictive of disease recurrence [12]. Since ctDNA status is proven to be useful as a surrogate marker for the presence of residual disease, the postchemotherapy ctDNA level could potentially be a more important marker for patient prognosis monitoring.

Additionally, it is worth noting that, given COVID-19, much surveillance imaging has been deferred due to the risk of coming to the hospital/clinics to get a scan [42, 43]. Noninvasive blood ctDNA monitoring, which can also be performed at home, may be one additional method of surveillance and decreasing contact and exposure during the COVID-19 pandemic [44, 45].

Our study has several limitations. First, because of the limited clinical application, the number of included studies was relatively small, although no significant heterogeneity was found among the studies. Several studies were still in the follow-up period; hence, the medium recurrence-free survival was not fully reported. The testing methods of ctDNA also varied among studies. Second, our studies are mainly from Europe and Australia, and studies from other geographic locations may also be needed in future updates. Third, we analyzed the prognostic value of ctDNA by cancer stage. However, the individual studies that were included did not report such data.

### Table 2 Subgroup analyses

| Subgroup | No. of studies | HR | 95% CI | P value |
|----------|----------------|----|--------|---------|
| Year of publication | | | | |
| 2016 | 1 | 18.00 | 1.95 | 34.05 | 0.028 |
| 2017 | 1 | 36.77 | (128.88) | 202.42 | 0.664 |
| 2018 | 1 | 3.80 | (0.20) | 7.80 | 0.063 |
| 2019 | 4 | 6.62 | 1.74 | 11.49 | 0.008 |
| Setting | | | | |
| Australia | 4 | 7.76 | 2.07 | 13.45 | 0.008 |
| Denmark | 2 | 7.27 | (0.87) | 15.41 | 0.080 |
| German | 1 | 3.80 | (0.20) | 7.80 | 0.063 |
| Include IV stage | | | | |
| No | 4 | 8.25 | 3.02 | 13.47 | 0.002 |
| Yes | 3 | 3.96 | 0.23 | 7.70 | 0.037 |
| Overall | 7 | 5.41 | 2.37 | 8.45 | <0.001 |

CI confidence interval, HR hazard ratio
Conclusion

In brief, successive monitoring of ctDNA status and follow-up with postoperative CT/MRI are useful tools to detect early recurrence in postoperative ctDNA-positive patients.

Author contribution J.J.P. contributed to conception and design; Y.K.C., S.B.M., and Y.Q.L. contributed to development of methodology; Y.K.C., S.B.M., M.D.W., Y.Q.L., and X.C. contributed to acquisition of data; Y.K.C., M.D.W., and X.C. contributed to analysis and interpretation of data; Y.K.C., S.B.M., M.D.W., and X.C. contributed to writing of the manuscript; Y.Q.L. and J.J.P. contributed to review and revision of the manuscript; J.J.P. contributed to study supervision. All authors approved the final version of the manuscript, including the authorship list.

Funding National Natural Science Foundation of China; Grant numbers U1932145 (to Junjie Peng); Science and Technology Commission of Shanghai Municipality; Grant Number: 18401933402 (to Junjie Peng); National Natural Science Foundation of China; Grants Number: 82002946 (to Yaqi Li); “ChenGuang Program” supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission; Grant Number: 20CG08 (to Yaqi Li); Shanghai Sailing Program; Grant Number: 22YF1408800 (to Shaobo Mo) and 19YF1409500 (to Yaqi Li).

Availability of data and materials The dataset used during the study are available from the corresponding author on a reasonable request.

Declarations

Consent for publication Not applicable.

Competing interests The authors declare no competing interests.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33
2. Christoforl G (2006) New signals from the invasive front. Nature 441:444–450
3. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cerkez A, Smith RA, Jemal A (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145–164
4. Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T et al (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20898 patients on 18 randomized trials. J Clin Oncol 27:872–877
5. Sveen A, Kopetz S, Lothe RA (2020) Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 17:11–32
6. Rockall TA, McDonald PJ (1999) Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis 14:73–77
7. Shinkins B, Nicholson BD, Primrose J, Perera R, James T, Pugh S, Mant D (2017) The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLoS One 12:e0171810
8. Su BB, Shi H, Wan J (2012) Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol 18:2121–2126
9. Young GP, Pedersen SK, Mansfield S, Murray DH, Baker RT, Rabbitt P, Byrne S, Bambacas L, Hollington P, Symonds EL (2016) A cross-sectional study comparing a blood test for methylated BCA1I and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Med 5:2763–2772
10. Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R (2016) DNA methylation based biomarkers in colorectal cancer: a systematic review. Biochim Biophys Acta 1866:106–120
11. Rasmussen SL, Krarup HB, Sunesen KG, Pedersen IS, Madsen PH, Thorlacius-Ussing O (2016) Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. Colorectal Dis 18:549–561
12. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra92
13. Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Chحادour AD, Oxnard GR (2021) Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA Cancer J Clin 71:176–190
14. Jin S, Zhu D, Shao F, Chen S, Guo Y, Li K et al (2021) Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci USA 118
15. Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H et al (2019) Analysis of plasma cell-free DNA by ultradepth sequencing in patients with stages I to III colorectal cancer. JAMA Oncol 5:1124–1131
16. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ et al (2018) Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 36:1631–1641
17. Murray DH, Symonds EL, Young GP, Byrne S, Rabbitt P, Roy A, Cornthwaite K, Karapetis CS, Pedersen SK (2018) Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. J Cancer Res Clin Oncol 144:1741–1750
18. Cai G, Cai M, Feng Z, Liu R, Liang L, Zhou P et al (2021) A multilocus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer. Gastroenterology 161:2053-2056.e2
19. Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M et al (2019) Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol 5:1710–1717
20. Wang Y, Li L, Cohen JD, Kinde I, Ptak J, Popoli M et al (2019) Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncol 5:1118–1123
21. Wong R, Tie J, Lee M, Cohen J, Wang Y, Li L et al (2019) The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. Int J Cancer 145:540–547
22. Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K et al (2019) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut 68:663–671
23. Scholer LV, Reinert T, Ørntoft MW, Kassentoft CG, Årnadóttir SS, Vang S et al (2017) Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res 23:5437–5445
24. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537–540

25. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24

26. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361:2449–2460

27. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558

28. Nguyen LH, Goel A, Chung DC (2020) Pathways of colorectal carcinogenesis. Gastroenterology 158:291–302

29. McPhail S, Zhao X, Qin ZZ, Steele R, Benedetti A (2019) One-sample aggregate data meta-analysis of medians. Stat Med 38:969–984

30. Chao M, Gibbs P (2009) Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J Clin Oncol 27:e279–80; author reply e281

31. Shin SJ, Chun SM, Kim TI, Kim YJ, Choi HJ, Jang SJ, Kim J (2017) Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PLoS One 12:e0176340

32. Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J et al (2013) Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open 3:e003055

33. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394:1467–1480

34. McPhail S, Johnson S, Greenberg D, Peake M, Rous B (2015) Stage at diagnosis and early mortality from cancer in England. Br J Cancer 112(Suppl 1):S108–S115

35. Young PE, Womeldorph CM, Johnson KE, Maykel JD, Brucher B, Stojadinovic A, Avital I, Nissan A, Steele SR (2014) Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. J Cancer 5:262–271

36. Mo S, Dai W, Xiang W, Li Y, Feng Y, Zhang L, Li Q, Cai G (2019) Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer. Carcinogenesis 40:861–870

37. Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH, Laurent-Puig P (2002) Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100:542–548

38. Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, Alexandersen K, Huang YS, Tzou WS, Lin SR (2004) Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 28:721–726

39. Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA (2014) Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14:336

40. Field K, Lipton L (2007) Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 13:3806–3815

41. Bergheim J, Semaan A, Gevensleben H, Groening S, Knoblich A, Dietrich J, Weber J, Kalff JC, Bootz F, Kristiansen G, Dietrich D (2018) Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. Br J Cancer 118:1217–1228

42. Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD (2021) Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. JAMA Oncol 7:458–460

43. Morris EJA, Goldacre R, Spata E, Matham M, Finan PJ, Shelton J et al (2021) Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. Lancet Gastroenterol Hepatol 6:199–208

44. Thierry AR, Pastor B, Pisareva E, Ghiringhelli F, Bouché O, De La Foucauldère C et al (2021) Association of COVID-19 lockdown with the tumor burden in patients with newly diagnosed metastatic colorectal cancer. JAMA Netw Open 4:e2124483

45. Crigna AT, Samec M, Koklesova L, Liskova A, Giordano FA, Kubatka P, Golubnitschaja O (2020) Cell-free nucleic acid patterns in disease prediction and monitoring-hype or hope? Epma J 11:1–25

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.